CLAIMS

1. A pharmaceutical composition for treating a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets, comprising:

   - Nimotuzumab monoclonal antibody; and

   - a compound against the NeuGcGM3 ganglioside being vaccine having NeuGcGM3/VSSP as active principle or Racotumumab anti-idiotypic vaccine adjuvated with alumina.

2. The composition of claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.

3. The composition of claim 2 wherein the tumor is a cancer selected from the group comprising non-small cell lung cancer, stomach, colorectal, pancreas, liver, bladder, glioblastoma and non-Hodgkin lymphoma.

4. The composition of claims 1 to 3 in combination with conventional radiotherapy.

5. The composition of claims 1 to 3 in combination with conventional chemotherapy.

6. The composition of claims 1 to 3 in combination with conventional radiotherapy and chemotherapy.

CLAIMS

1. The use of a pharmaceutical composition in the manufacture of a medicament for the treatment of a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets, comprising:

   - Nimotuzumab monoclonal antibody; and
   - a compound against the NeuGcGM3 ganglioside being vaccine having NeuGcGM3/VSSP as active principle or Racotumumab anti-idiotypic vaccine adjuvated with alumina.

2. The use according to claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.

3. The use according to claim 2 wherein the cancer is a tumor selected from the group comprising non-small cell lung cancer, stomach, colorectal, pancreas, liver, bladder, glioblastoma and non-Hodgkin lymphoma.

4. The use according to any of the claims 1 to 3 in combination with conventional radiotherapy.

5. The use according to any of the claims 1 to 3 in combination with conventional chemotherapy.

6. The use according to any of the claims 1 to 3 in combination with conventional radiotherapy and chemotherapy.